Investing News Network

Markets
TSX18861.36-217.28
TSXV617.26-9.08
DOW31097.26+321.83
S&P 5003825.33+39.95
NASD11127.85+99.11
ASX6539.90-28.20
Commodities
Gold1809.28-0.76
Silver19.87+0.01
Copper3.62-0.09
Palladium1961.00+5.92
Platinum891.50+3.22
Oil108.43+2.67
Heating Oil3.97+0.14
Natural Gas5.68+0.07
Currencies
BTCUSD19310.21-10.45
USDCAD1.2881+0.0095
USDEUR0.9585-0.0003
USDGBP0.8259-0.0010
USDAUD1.4657-0.0031
USDJPY135.24+0.16

Cronos Group Partners with Geocann to Leverage VESIsorb® Delivery Technology for Faster Absorption

Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) ("Cronos" or the "Company") is pleased to announce the launch of the first of what is expected to be a range of products, in partnership with Geocann, which will utilize the advanced VESIsorb ® delivery system. This technology provides better bioavailability and faster absorption. VESIsorb ® formulations have set the industry benchmark in peer-reviewed published studies, delivering superior pharmacokinetic performance, including fast absorption, higher plasma concentration, and greater area under the curve.

"We are committed to bringing breakthrough innovations to the market, providing consumers with differentiated and high-quality products," said Mike Gorenstein, Chairman, President and Chief Executive Officer, Cronos. "Working with Geocann's technology enables us to expand our product offering to bring consumers a fast-acting cannabinoid product with a quicker onset than previously available, along with improved efficacy, helping enhance and differentiate effect and experience."

Keep reading... Show less

Cronos Group Inc. Announces Results of 2022 Annual Meeting of Shareholders

Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) ("Cronos" or the "Company") announces that at its Annual Meeting of Shareholders held on June 23, 2022 (the "Meeting") shareholders voting in person or by proxy held in total 265,763,587 common shares of the Company, representing 70.76% of the total number of common shares of the Company outstanding.

Each of the directors listed as a nominee in the Company's proxy statement dated April 29, 2022 (the "Proxy Statement") was elected as a director of the Company, with each director receiving in excess of 91.6% of the votes cast in favor of his or her election. The detailed results of the vote for the election of directors are as follows:

Keep reading... Show less

Cronos Group and Ginkgo Bioworks Announce Achievement of THCV Equity Milestone

Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) ("Cronos"), an innovative global cannabinoid company, and Ginkgo Bioworks (NYSE: DNA) ("Ginkgo"), the leading horizontal platform for cell programming, today announced the achievement of the third target productivity milestone in their partnership to produce eight cultured cannabinoids. Using Ginkgo's platform for organism design and development, Cronos has successfully achieved the productivity target for tetrahydrocannabivarin (THCV), a cannabinoid hypothesized to reduce the appetite-enhancing property of THC. Access to additional rare cannabinoids will support Cronos' innovation pipeline and commercialization strategy.

Keep reading... Show less
×